

Protein content (mg/mL)
60
58
56
54
52
50
48
46
44
42
40
Time 0
4 weeks 40°C
1
2
3
4
5
6
7
8
9
10
ADAM
RMP (US)
RMP (EU)
Formulation #

FIG. 1



Aggregates (%)
1.0
0.5
0.0
Time 0
2 weeks 40°C
4 weeks 40°C
1
2
3
4
5
6
7
8
9
10
ADAM
RMP (US)
RMP (EU)
Formulation #

FIG. 2



Time 0
2 weeks 40°C
4 weeks 40°C
Fragments (%)
0
1
2
1
2
3
4
5
6
7
8
9
10
ADAM
RMP (US)
RMP (EU)
Formulation #

FIG. 3



Unfolding temperature (°C)
50
55
60
65
70
75
1
2
3
4
5
6
7
8
9
10
ADAM
RMP (US)
RMP (EU)
Formulation #

FIG. 4



Aggregates (%)
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Time 0
2 weeks (40°C)
4 weeks (40°C)
DoE2-1
DoE2-2
DoE2-3
Humira US
Humira EU

FIG. 5



Fragments (%)
3.0
2.5
2.0
1.5
1.0
0.5
0.0
Time 0
2 weeks (40°C)
4 weeks (40°C)
DoE2-1
DoE2-2
DoE2-3
Humira US
Humira EU

FIG. 6



Time 0
2 weeks 40°C
4 weeks 40°C
Main peak (%)
60
55
50
45
40
35
30
DoE-1
DoE-2
DoE-3

FIG. 7



Time 0
2 weeks 40°C
4 weeks 40°C
Acidic cluster (%)
35
30
25
20
15
10
5
0
DoE-1
DoE-2
DoE-3

FIG. 8



Time 0
2 weeks (40°C)
4 weeks (40°C)
Turbidity (NTU)
11
11
10
10
9
9
8
DoE2-1
DoE2-2
DoE2-3

FIG. 9



Time 0
24 hrs
48 hrs
Total aggregates (%)
0.45
0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00
DoE2-1
DoE2-2
DoE2-3

FIG. 10



Time 0
24 hrs
48 hrs
Fragments (%)
0.50
0.45
0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00
DoE2-1
DoE2-2
DoE2-3

FIG. 11



Time 0
24 hrs
48 hrs
Turbidity (NTU)
20
18
16
14
12
10
8
6
4
2
0
DoE2-1
DoE2-2
DoE2-3

FIG. 12



Time 0
After exposure
Aggregates (%)
16
14
12
10
8
6
4
2
0
DoE2-1
DoE2-2
DoE2-3
Ref US
Humira EU

FIG. 13



Before
After
Fragments (%)
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
DoE2-1
DoE2-2
DoE2-3

FIG. 14



Before
After
Main Peak (%)
70
60
50
40
30
20
10
0
DoE2-1
DoE2-2
DoE2-3
Humira US
Humira EU

FIG. 15



Before
After
Acidic cluster (%)
70
60
50
40
30
20
10
0
DoE2-1
DoE2-2
DoE2-3
Humira US
Humira EU

FIG. 16



15
13
11
9
7
5
3
1
-1
Turbidity (NTU)
Time 0
After exposure
DoE2-1
DoE2-2
DoE2-3

FIG. 17



20.0
19.0
18.0
17.0
16.0
15.0
14.0
13.0
12.0
11.0
10.0
Main Peak (%)
Time 0
5X FT
DoE2-1
DoE2-2
DoE2-3

FIG. 18



60.0
59.0
58.0
57.0
56.0
55.0
54.0
53.0
52.0
51.0
50.0
Acidic cluster (%)
Time 0
5X FT
DoE2-1
DoE2-2
DoE2-3

FIG. 19



1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
Aggregates (%)
T0
After 5X FT
DoE2-1
DoE2-2
DoE2-3

FIG. 20



500
450
400
350
300
250
200
150
100
50
0
SVP ≥ 10 micron (#/mL)
T0
After 5X FT
DoE2-1
DoE2-2
DoE2-3

FIG. 21



100
90
80
70
60
50
40
30
20
10
0
SVP ≥ 25 micron (#/mL)
T0
After 5X FT
DoE2-1
DoE2-2
DoE2-3

FIG. 22